Advertisement
Home Tags Cancer: Skin

Tag: Cancer: Skin

For organ recipients in Norway

In Norway, Risk of SCC After Organ Transplant Has Fallen

Standardized incidence ratio peaked in patients who underwent transplantation in 1983-1987 period
The American Joint Committee on Cancer melanoma staging system has been revised

Melanoma Staging Undergoes Evidence-Based Revision

Key changes include new N category descriptors, more stage III subgroups, new M1D designation
Overall survival for patients with melanoma brain metastases has improved significantly since 2000

Overall Survival Up for Melanoma Brain Metastases

Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months
The U.S. Preventive Services Task Force (USPSTF) recommends that fair-skinned individuals aged 6 months to 24 years and parents of young children be counseled regarding skin protection behaviors

USPSTF Recommends Counseling Youth on Sun Protection Behavior

Counseling should be provided to fair-skinned individuals aged 6 months to 24 years, parents
Patients diagnosed with melanoma are more likely to have treatment delays if they are nonwhite or on Medicaid

Insurance Type Linked to Surgery Delay in Melanoma

Surgical treatment delays increased for Medicaid versus private patients, for nonwhite patients
For patients with melanoma

Propranolol Use Inversely Linked to Melanoma Recurrence

Patients taking propranolol as off-label adjuvant treatment had reduced risk of recurrence
Solar occupational ultraviolet exposure is a major determinant of incident squamous cell carcinoma

Skin Cancer Prevention Strategies Needed in Work Settings

High occupational UV exposure tied to two-fold increase in skin cancer risk
Adjuvant therapy with nivolumab is associated with longer recurrence-free survival than therapy with ipilimumab among patients undergoing resection of stage IIIB

Adjuvant Nivolumab Tops Ipilimumab in Melanoma

Longer recurrence-free survival for stage IIIB, IIIC, IV melanoma
For patients with resected stage III melanoma with BRAF V600E or V600K mutations

Dabrafenib, Trametinib Beneficial in Resected Melanoma

Rate of relapse-free survival up for resected stage III melanoma with BRAF V600E, V600K mutations
The majority of melanomas arise from new lesions rather than existing moles

Most Melanomas Don’t Start As Existing Moles

More than two-thirds occur as new lesions, researchers find